Amicus Therapeutics Company Description

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.

The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease.

It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold.

Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics, Inc.

Country	United States
Founded	2002
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	499
CEO	Bradley Campbell

Contact Details

Address: 47 Hulfish Street Princeton, New Jersey 08542 United States
Phone	609 662 2000
Website	amicusrx.com

Stock Details

Ticker Symbol	0HF9
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US03152W1099
SIC Code	2836

Key Executives

Name	Position
Bradley L. Campbell M.B.A.	Chief Executive Officer, President and Director
Simon Nicolas Reade Harford	Chief Financial Officer
Ellen S. Rosenberg J.D.	Chief Legal Officer and Corporate Secretary
David M. Clark	Chief People Officer
Dr. Jeffrey P. Castelli Ph.D.	Chief Development Officer
Samantha L. Prout	Chief Accounting Officer and Controller
Dr. Jill Weimer Ph.D.	Chief Science Officer
Andrew Faughnan	Vice President of Investor Relations
Patrik S. Florencio Esq.	Global Chief Compliance and Risk Officer
Brendan McEvoy	Executive Director of External Communications